Imugene Limited (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Limited (ASX: IMU)
Latest News
Share Market News
ASX 200 midday update: Carsales sinks, Liontown jumps on Ford agreements
Share Fallers
Why Appen, BWX, Imugene, and Wesfarmers shares are dropping
Share Market News
ASX 200 midday update: Tech shares tumble, Collins Foods jumps
Share Market News
Here are the 3 most heavily traded ASX 200 shares on Monday
Share Gainers
Why Imugene, Link, Metcash, and Sayona shares are racing higher
Healthcare Shares
'Significant milestone': Why the Imugene share price is soaring 30% today
Share Market News
ASX 200 midday update: Metcash and Imugene jump, Evolution downgrades guidance again
Healthcare Shares
Why is the Imugene share price one of the biggest ASX 200 fallers today?
Share Fallers
These were the worst performing ASX 200 shares last week
Healthcare Shares
'Storm in a teacup': Why the Imugene share price is lifting 14% today
Healthcare Shares
Imugene share price surges 18% to lead the ASX 200 on Thursday
Share Gainers
2 ASX All Ordinaries shares having a cracking day, despite the carnage
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imugene Limited
Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.
The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.
The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu.
Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.
